Low Float Nasdaq Breakout Idea (BSGM) Is A MedTech Company And Potential Squeeze Candidate (Details Now)
$13.00 Laidlaw & Company Price Target
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death globally.
In fact, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths.
Of these deaths, 85% were due to heart attack and stroke.
Cardiovascular devices are medical devices designed for monitoring, preventing, diagnosing, and treating diseases associated with the cardiovascular system or heart related diseases.
The market for these devices was valued at $40.8Bn in 2018 and it is projected to reach $71.1Bn in 2027; it is expected to grow at a CAGR of 6.5% from 2019 to 2027.
And, one company's game-changing first product could impact this market greatly as it aims to provide physicians with a better idea of heart related issues.
That's why for Wednesday, June 30th there is only one Nasdaq profile to have on your radar:
*BioSig Technologies, Inc. (BSGM)*
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Here’s Why PURE EP Could Be a Game-Changer
According to XTalks, PURE EP could fill a significant need because:
“The electrograms used today can be riddled with noise and artifacts coming from other equipment found in the operating room. Such a procedure can take up to six hours, potentially yielding what is referred to in the industry as a ‘dirty signal’ that’s indiscernible to interpret by many electrophysiologists.” (1)
BioSig's PURE EP was developed to address unmet needs in a large and growing market and deliver technology to improve catheter ablation treatments for arrhythmias, Atrial Fibrillation, and Ventricular Tachycardia.
“The system is intended to acquire, digitize, amplify, filter, measure and calculate, display, record and store electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data,” as further reported XTalks. (1)
Furthermore, BioSig Technologies' PURE EP system has: (2)
A signal processing platform designed to reveal the full range of cardiac signals and provide electrophysiologists with signal clarity during procedures.
The ability to refine signal clarity by reducing signal noise with higher precision.
The potential to allow surgeons to work far more accurately, decreasing the probability of a repeat procedure and increasing procedure safety.
Even more impressive, the PURE EP Systems are already installed at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic’s Florida campus, Massachusetts General Hospital, the University of Pennsylvania, and Deborah Heart and Lung Center. (3)
No. 1 Potential Immediate Term Catalyst - Company's Tech To Be Featured At Stanford Retreat
BioSig’s Signal Processing Technology for Electrophysiology To Be Featured During 2021 Stanford Biodesign New Arrhythmia Technologies Retreat
Westport, CT, June 28, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company would be presenting during 2021 Stanford Biodesign New Arrhythmia Technologies Retreat, due to take place virtually on July 27, 2021. The Company will present at 2 pm PT.
“We look forward to presenting a selection of impactful clinical examples that demonstrate the applications of our latest software tools during this year’s Stanford Biodesign Retreat. We would like to thank Dr. Wang and the faculty for the outstanding agenda that highlights innovation in this crucial area of arrhythmia care,” added Olivier Chaudoir, Senior Director of Marketing of BioSig Technologies, Inc.
Read the full article here.
No. 2 Potential Immediate Term Catalyst - Potential Squeeze On Horizon?
Check out BSGM's 6-month chart below: